Skip to main navigation Skip to search Skip to main content

Comparación de medicamentos sujetos a control según el Observatorio Peruano de Productos Farmacéuticos

Translated title of the contribution: Comparison of drugs subject to control according to the Peruvian Observatory of Pharmaceutical Products
  • Pedro Wong
  • , Jeel Moya-Salazar
  • , Hans Contreras-Pulache
  • Universidad Norbert Wiener

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The difference between moderate and rigid control of medicines constitutes a complex process that leads to errors by the pharmaceutical establishment during the availability and sale of medicines. Objective: To compare the Observatory's information for drugs under a moderate and rigid control regime in private pharmaceutical establishments in Lima, Peru. Methods: In this quantitative study, open-access secondary data from the Observatory were analyzed according to the list of controlled drugs of the Peruvian General Directorate of Supplies, Medicines and Drugs (Dirección General de Insumos, Medicamentos y Drogas del Perú). List IIA (rigid regulation) and IVB (moderate regulation) drugs were evaluated, and the variables available in the Observatory were compared with parametric and nonparametric statistics. Results: Controlled drugs were differentiated by sales establishments (p = 0.001), and their average cost according to private (p = 0.035) and public (p = 0.003) marketing. IIA drugs showed lower availability and higher price with respect to IVB drugs. Conclusions: Rigidly controlled drugs are less available and more expensive.

Translated title of the contributionComparison of drugs subject to control according to the Peruvian Observatory of Pharmaceutical Products
Original languageSpanish
Article numbere2008
JournalRevista Cubana de Investigaciones Biomedicas
Volume43
StatePublished - 3 Jan 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'Comparison of drugs subject to control according to the Peruvian Observatory of Pharmaceutical Products'. Together they form a unique fingerprint.

Cite this